| Literature DB >> 12655297 |
U Fischer1, R U Jänicke, K Schulze-Osthoff.
Abstract
Apoptotic cell death is executed by the caspase-mediated cleavage of various vital proteins. Elucidating the consequences of this endoproteolytic cleavage is crucial for our understanding of cell death and other biological processes. Many caspase substrates are just cleaved as bystanders, because they happen to contain a caspase cleavage site in their sequence. Several targets, however, have a discrete function in propagation of the cell death process. Many structural and regulatory proteins are inactivated by caspases, while other substrates can be activated. In most cases, the consequences of this gain-of-function are poorly understood. Caspase substrates can regulate the key morphological changes in apoptosis. Several caspase substrates also act as transducers and amplifiers that determine the apoptotic threshold and cell fate. This review summarizes the known caspase substrates comprising a bewildering list of more than 280 different proteins. We highlight some recent aspects inferred by the cleavage of certain proteins in apoptosis. We also discuss emerging themes of caspase cleavage in other forms of cell death and, in particular, in apparently unrelated processes, such as cell cycle regulation and cellular differentiation.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12655297 PMCID: PMC7091709 DOI: 10.1038/sj.cdd.4401160
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828
List of known caspase substrates
| Substrateb | Physiological Function | Cleavage effect | Consequences of Cleavage | Cleavage sitesa | References |
|---|---|---|---|---|---|
|
| |||||
| Apaf-1 | Apoptosome component | Inactivated? | SVTD (271) and a second unknown site | ||
| Bad | Proapoptotic Bcl-2 protein | Activated | Cleavage product proapoptotic, if overexpressed | Human: EQED (14) |
|
| Mouse: SATD (61) | |||||
| Bax | Proapoptotic Bcl-2 protein | Unknown | FIQD (33) | ||
| Bcl-2 | Apoptosis inhibitor | Inactivated | Generation of a proapoptotic fragment | DAGD (34) |
|
| Bcl-xL | Apoptosis inhibitor | Inactivated | Generation of a proapoptotic fragment | HLAD (61), SSLD (76) | |
| Bid | Apoptosis activator | Activated | Generation of a proapoptotic fragment that is myristoylated; phosphorylation inhibits cleavage | LQTD (59) | |
| c-FLIP | Caspase-8 inhibitor | LEVD (376) |
| ||
| c-IAP1 | Caspase inhibitor | Inactivated | Generation of a proapoptotic fragment | ENAD (372) |
|
| Procaspases | Procaspase-1-14 | Activated | Activation by proteolytic processing | XXXD | For a review see: Earnshaw |
| XIAP | Caspase inhibitor | Inactivated? | Generation of two fragments with distinct inhibitory activity for caspase-3, -7 and -9. Cleaved XIAP is less antiapoptotic and ineffective to activate NF- | SESD (242) | |
|
| |||||
| APC | Adenomatous polyposis coli protein | Cleavage separates ß-catenin binding region and N-terminal armadillo repeat | DNID (777) | ||
| CALM | Clathrin assembly protein of myeloid leukemia (syn. AP180), promotes assembly of clathrin triskelia into clathrin cages | Inactivated | Unknown |
| |
| Cas | Crk-associated substrate (p130cas), associates with FAK, paxillin, involved in integrin signaling | Inactivated | Contributes to disassembly of focal adhesion complexes, interrupts extracellular survival signals | DVPD (416), DSPD (748) | |
| Cell adhesion and WNT/wingless signaling pathway, constituent of adherens junctions | Inactivated | Reduced | SYLD (32), ADID (83), TQFD (115), YPVD (751), DLMD (764) | ||
| Adherens junction protein (syn. plakoglobin) | Inactivated | Relocalization to the cytoplasm, involved in cell dismantling | Unknown | ||
| Desmoglein-3 | Major transmembrane component of desmosomes | Inactivated | Loss of cell–cell contacts | DYAD (781) and additional unknown sites |
|
| Desmocollin 3 | Component of desmosomes | Inactivated | Loss of cell–cell contacts | Unknown |
|
| Desmoplakin | Desomoplakin-1, -2, components of desmosomes | Inactivated | Loss of cell–cell contacts | Unknown |
|
| E-cadherin | Calcium-dependent adhesion protein in adherens juctions | Inactivated | Rather late cleavage may contribute to disruption of cell–cell contacts | DTRD (750) | |
| N-cadherin | Calcium-dependent cell adhesion protein | Inactivated | Unknown |
| |
| P-cadherin | Cell adhesion protein in adherens junctions | Inactivated? | Rather late cleavage may be involved in loss of cell–cell contacts | Putative site: ETAD (695) |
|
| FAK | Focal adhesion kinase, tyrosine kinase involved in formation of contact sites to extracellular matrix | Inactivated | Cleavage leads to disassembly of the focal adhesion complex, cell detachment and interruption of survival signals | DQTD (772) | |
| HEF1 | Human enhancer of filamentation 1, member of the docking protein family, involved in integrin signaling | Inactivated | Disruption of antiapoptotic integrin signaling | DLVD (363), DDYD (630) | |
| Connexin 45.6 | Lens gap junction protein | Inactivated | Cleavage at a noncanonical site; phosphorylation by casein kinase II prevents degradation | DEVE (367) |
|
| Paxillin | Component of the focal adhesion complex | Inactivated | Cleavage results in focal adhesion disassembly and detachment | Early: NPQD (102), SQLD (301) Late: DDLD (5), SELD (146), FPAD (165), SLLD (222) | |
| Plakophilin-1 | Component of desmosomes | Inactivated | Loss of cell–cell contacts | Unknown |
|
|
| |||||
| Cardiac actin, myofilament protein | Inactivated | Rather inefficient cleavage by caspase-3, involved in myofibrillar damage | Unknown |
| |
| Cytoskeleton | Inactivated | Cleavage has not been observed in all cell types | ELPD (244) | ||
| Cardiac myofilament protein, component of the Z band | Inactivated | Cleavage results in myofibrillar damage | Unknown |
| |
| Actin-capping protein involved in actin network organization | Inactivated | Cleavage results in loss of adducin from adherens junctions and may contribute to cell detachment | DDSD (633) |
| |
| CD-IC | Cytoplasmic dynein intermediate chain, mediates dynein/dynactin interaction | Inactivated | Cleavage destroys the cytoplasmic dynein complex and stops dynein-dependent membrane motility | DSGD (99) and an additional unknown site |
|
| Cortactin | Actin-binding and SH3-containing protein | Inactivated? | Probably involved in cytoskeletal reorganization | Unknown |
|
| Filamin | Actin-binding protein that crosslinks actin filaments and anchors membrane proteins to the cytoskeleton | Inactivated | Probably involved in cytoskeletal reorganization | Unknown | |
| Fodrin | Component of the membrane cortical cytoskeleton (syn. alpha II-spectrin) | Inactivated | Cleavage results in disruption of the cortical cytoskeleton and may contribute to membrane blebbing | ||
| Gas2 | Growth-arrest-specific 2 gene, involved in microfilament organization | Inactivated | Cleaved form specifically regulates microfilament and cell shape changes | SRVD (37) |
|
| Gelsolin | Actin-severing protein | Inactivated | Cleaved fragment triggers F-actin depolymerization and membrane blebbing | DQTD (403) | |
| HIP-55 | Actin-binding protein with SH3 domain, interacts with hematopoietic progenitor kinase-1 | Inactivated? | Cleavage dissociates the actin binding from the SH3 domain and leads to cytoskeletal reorganisation | EHID (361) |
|
| HS1 | Hematopoietic-specific protein 1 (syn. Lck-binding protein) | Inactivated? | Probably involved in cytoskeletal reorganization | Unknown |
|
| Keratins | Cytokeratin-14, -17, -18, -19, intermediate filament proteins | Inactivated | Cleavage may contribute to cellular collapse | Keratin 18: VEVD(238), DALD (397) | |
| MHC | Myosin heavy chain | Inactivated? | Identified by 2D gel electrophoresis, not confirmed by | Unknown |
|
| vMLC | Ventricular essential myosin light chain, cardiac myofilament protein | Inactivated | Cleavage at a noncanonical site results in myofibrillar damage, presumably involved in contractile dysfunction | DFVE (135) |
|
| p150Glued | Mediates dynein/dynactin interaction | Inactivated | Cleavage destroys the cytoplasmic dynein complex and stops dynein-dependent membrane motility | Unknown |
|
| Plectin | Abundant crosslinking protein of cytoplasmic filament systems | Inactivated | Reorganization of the microfilament sytem | ILRD (2395) |
|
| Component of the membrane cortical cytoskeleton | Inactivated | Cleavage results in disruption of cortical cytoskeleton and may contribute to membrane blebbing | DSLD (1478), DEVD (1457), ETVD (2146) |
| |
| Tau | Neuronal microtubule-associated protein | Inactivated | Cleavage generates a proapoptotic fragment, may be involved in neuronal disorders | DMVD (421) | |
| Troponin T | Cardiac troponin, myofilament protein | Inactivated | Cleavage contributes to myofibrillar damage and contractile dysfunction | VDFD (96) |
|
| Component of microtubuli | Inactivated? | Identified by 2D gel electrophoresis, not confirmed by | Unknown |
| |
| Vimentin | Intermediate filament specific for mesenchymal cells | Inactivated | Disruption of intermediate filaments and promotion of apoptosis | DSVD (85), IDVD (259), TNLD (429) | |
|
| |||||
| Emerin | Nuclear membrane-anchored protein mutated in Emery–Dreifuss muscular dystrophy, related to LAP2 | Inactivated | Cleavage may contribute to nuclear envelope breakdown | Unknown |
|
| LBR | Lamin B receptor; chromatin and lamin-binding protein in the inner nuclear membrane | Inactivated | Nuclear lamina disassembly | Unknown |
|
| Lamin A | Nuclear envelope protein | Inactivated | Nuclear lamina disassembly | VEID (230) | |
| Lamin B1 | Nuclear envelope protein | Inactivated | Nuclear lamina disassembly | VEVD (231) |
|
| Lamin C | Nuclear envelope protein | Inactivated | Nuclear lamina disassembly | VEID (230) |
|
| LAP2 | Lamin-associated polypeptide 2 | Inactivated | Impaired chromatin-binding properties | Putative sites: KRID (413) EERD (441), SQHD (483) |
|
| Nup153 | Nucleoporin 153, component of the nuclear pore and binding site for importin-ß | Inactivated | Impaired nuclear transport, redistrubution of importins | DITD (343) | |
| Nup214 | Nucleoporin 214, binding site for exportin | Inactivated | Impaired nuclear transport | Unknown |
|
| RanBP2 (Nup358) | Nucleoporin 358, Ran-binding protein-2 with SUMO E3 ligase activity | Inactivated | Impaired nuclear transport | Unknown |
|
| SAF-A | Scaffold attachment factor-A, DNA-binding protein involved in nuclear matrix stabilization | Inactivated | Loss of DNA binding and detachment from nuclear structural sites | SALD (100) | |
| SATB1 | Special AT-rich sequence-binding protein 1, T-cell-specific DNA-binding protein for nuclear matrix-associating DNAs, involved in gene expression | Inactivated | Cleaved protein dissociates from chromatin, may be involved in high molecular weight DNA fragmentation | VEMD (254) | |
| Tpr | Nuclear pore-associated filament protein; binding site for importin- | Inactivated | Impaired nuclear transport | Putative sites: DSQD (1892), DGTD (1999), DDED (2117), DDGD (2250), DESD (2285) |
|
|
| |||||
| p28BAP31 | Bcl-2 adaptor at the ER, originally identified as B-cell receptor-associated protein | Inactivated | BAP31 is cleaved by and recruits caspase-8 to the ER. Expression of cleaved product is proapoptotic and causes disturbed transport of proteins from ER to Golgi | AAVD (164) | |
| Golgin-160 | Golgi autoantigen, Golgin-3 (GOLGA3), located at the rims of cisternas | Inactivated | Cleavage by caspase-2 results in disintegration of the Golgi complex | ESPD (59), CSTD (139), SEVT (311) |
|
| GRASP65 | Golgi reassembly and stacking protein of 65 kDa | Inactivated | Golgi disassembly and loss of integrity | SLLD (320), SFPD (375), TLPD (393) |
|
| Kinectin | ER-resident receptor for molecular motor kinesin, involved in microtubule-based vesicle transport | Unknown | Preferentially cleaved by caspase-7 | Unknown |
|
|
| |||||
| c-Abl | Tyrosine kinase involved in cell cycle arrest | Inactivated | Cleavage-mediated inactivation may suppress erythropoiesis | Putative sites: DTTD (546), DTAD (655) |
|
| Bcr-Abl | Constitutively active fused gene product of c-Abl and Bcr in chronic myeloid leukemia | Inactivated | See c-Abl |
| |
| Cdc6 | Required for prereplicative complex formation | Inactivated | Cleavage results in loss of chromatin binding | LVRD (99), SEVD (442) |
|
| CDC27 | Cdc2 and Cdk-inhibitory kinase of the anaphase-promoting complex | Inactivated | Cleavage results in increased Cdk activity | Unknown |
|
| Cyclin A | Inactivated | The cleavage site of | DEPD (90) |
| |
| Cyclin E | Regulator of G1/S cell cycle progression | Inactivated | Elimination of Cdk2 interaction, results in inactivation of cdk kinase. Overexpression of the p18 fragment triggers apoptosis | Unknown |
|
| MDM2/HDM2 | Mouse/human double minute chromosome oncogene 2, controls degradation of p53 | Inactivated | The cleaved MDM2 loses the ability to promote p53 degradation and functions in a dominant-negative fashion to stabilize p53 | DVPD (361) | |
| MDMX | p53-binding protein homologous to MDM2, which promotes degradation of p53. | Inactivated | In analogy to MDM2, cleaved MDMX does not degrade p53 and functions in a dominant-negative fashion to stabilize p53 | DVPD (361) |
|
| NuMA | Nuclear mitosis apparatus protein, translocates to spindle poles at mitosis | Inactivated | Cleavage causes redistribution of NuMA and contributes to nuclear disruption | DSLD (1712) | |
| p21Waf1 | Cdk2 inhibitor involved in G1/S arrest | Inactivated | Loss of N-terminal cdk-inhibitory domain results in a reduced association with cyclin-cdk2 complexes and increased cdk2 activity | DHVD (112) | |
| p27Kip1 | Cdk2 inhibitor | Inactivated | Cleavage results in reduced association with cyclin-cdk2 complexes and increased cdk2 activity. | DPSD (139), ESQD (108) | |
| PITSLRE | Cell cycle-regulatory cdc2-like kinase | Activated? | Several isoforms are cleaved and presumably activated. Expression of a fragment-like mutant induces apoptosis | YVPD (391) | |
| Prothymosin- | Involved in cell proliferation | Inactivated | Cleavage prevents nuclear localization, proliferation-inducing ability is abolished | Three overlapping sites at the C-terminus: DDEDDDVD(101) | |
| Rb | Retinoblastoma protein, phosphorylation-controlled cell cycle regulator that binds to E2F-1 | Inactivated | Rb is cleaved in its hypophosphorylated form which results in unopposed E2F-1 action and reduced antiapoptotic activity | DEAD (886) |
|
| Wee1 | Inhibitory kinase of cdc2 and cdk2 | Inactivated | Cleavage-mediated inhibition results in elevated cdk activity | Unknown |
|
|
| |||||
| Acinus | ‘Apoptotic chromatin condensation inducer in the nucleus’ | Activated | Essential mediator of chromatin condensation | DELD (1093) |
|
| ATM | Ataxia telangiectasia mutated protein; kinase involved in the p53 DNA repair pathway | Inactivated | Cleavage abrogates kinase activity. Fragment is DNA binding and functions as a dominant-negative inhibitor | DYPD (863) |
|
| BLM | RECQ-like helicase, defective in Bloom's syndrome, involved in DNA replication and repair | Inactivated | Fragment retains helicase activity, albeit interaction with topoisomerase III | TEVD (415) | |
| BRCA-1 | Breast cancer suppressor protein, mediates cell cycle arrest and DNA repair | Inactivated | Expression of a noncleavable BRCA-1 attenuates apoptosis | DLLD (1154) |
|
| DNA-PKcs | DNA-dependent protein kinase catalytic subunit; involved in repair of DNA breaks and nucleotide excision repair | Inactivated | Loss of catalytic activity | DEVD (2713) | |
| ICAD | Inhibitor of caspase-activated DNase (syn. DFF45) | Inactivated | Cleavage liberates the active CAD endonuclease | DETD (117), DAVD (224) | |
| Helicard | CARD-containing DNA helicase | Activated | Involved in chromatin remodeling. Cleavage separates the CARD from the helicase domain and induces nuclear translocation | DNTD (208), SCTD (251) |
|
| MCM3 | ‘Minichromosome maintenance protein 3’, replication factor of the MCM complex, restricts replication to one round per cell cycle | Inactivated | Probably destruction of the MCM complex, prevention of replication | Unknown |
|
| PARG | Poly(ADP-ribose) glycohydrolase; removes poly(ADP-ribose) residues from proteins | Unknown | Cleavage does not alter enzymatic activity | DEID (256), MDVD (307) |
|
| PARP-1 | Poly(ADP-ribose) polymerase-1; involved in DNA repair and gene expression | Inactivated | Cleavage results in loss of catalytic activity and may prevent depletion of ATP which is required for apoptosis. | DEVD (214) | |
| PARP-2 | Poly(ADP-ribose) polymerase-2; involved in DNA repair | Inactivated | Cleavage between DNA binding and catalytic domain | LQMD (186) |
|
| Pol ɛ | DNA polymerase epsilon (pol | Inactivated | Cleavage dissociates the N-terminal catalytic core from the C-terminus; can no longer bind PCNA or other Pol ɛ subunits | DQLD (189), DMED (1185) |
|
| RAD21 | Component of the cohesin complex | Inactivated | Proapoptotic cleavage product | DSPD (279) |
|
| RAD51 | Human recombinase HsRad51 (homologous to RecA). Involved in homologous recombination and DNA repair | Inactivated | Cleavage products lack recombinase activity | DVLD (187) |
|
| RFC140 | Replication factor C (syn. DSEB), DNA-dependent ATPase of the replication factor complex, involved in DNA replication and repair | Inactivated | Cleavage separates the DNA binding from its association domain and impairs DNA replication | DEVD (722) | |
| Topo I | Topoisomerase I, breaks and rejoins DNA single strands | No effect? | Unconventional cleavage sites. Fragment still binds and cleaves DNA | DDVD (146), PEDD (123), EEED (170) | |
| Topo II | Topoisomerase II | Unknown | Unknown |
| |
| XRCC4 | X-ray repair, complementing defective, in Chinese hamster 4; involved in DNA double-strand break repair and V(D)J recombination | Inactivated | Inhibition of DNA repair | Unknown |
|
|
| |||||
| AP-2 | Inducible transcription factor | Inactivated | Loss of DNA-binding activity | DRHD (19) |
|
| CREB | cAMP response element-binding protein | Inactivated | Antiapoptotic function is abolished | Putative site: ILND (140) or LSSD (144) |
|
| c-Rel | NF- | Inactivated | Loss of transcriptional activity | Unknown |
|
| GAL4 | Yeast transcription factor used in two-hybrid assays | Inactivated | Cleavage results in loss of transcription in reporter gene assays | Unknown C-terminal cleavage sites |
|
| GATA-1 | Erythropoietic transcription factor | Inactivated | Loss of transcriptional activity results in impaired erythroblast development | EGLD (42), EDLD (125), LSPD (144) |
|
| HSF | Heat shock factor | Inactivated | Protective induction of heat shock response genes is abolished | Unknown |
|
| hTAF(II)80 δ | Specialized isoform of basal transcription factor TFIID subunit hTAF80 | Unknown | Elevated expression of hTAF(II)80 delta triggers apoptosis | Unknown |
|
| I | Inhibitor of NF- | Activated | Cleavage generates a constitutive inhibitor | DRHD (32) |
|
| LEDGF | Lens epithelium-derived growth factor, transcriptional coactivator | Inactivated | Cleavage abolishes survival function | EVPD (30), WEID (85), DAQD (486) |
|
| Max | Myc-associated factor | Inactivated | Cleavage by caspase-5 and -7 at an unusual glutamic acid residue | IEVE (10), SAFD (135) |
|
| MEF2A, C, D | Myocyte enhancer factor 2, isoforms A, C and D | Inactivated | Caspase cleavage generates a proapoptotic fragment with decreased transcriptional activity | MEF2A: SSYD (466), MEF2C: SSYD (422), MEF2D: LTED (288), DHLD (291) | |
| NF- | Subunit of NF- | Inactivated | Loss of DNA binding | Unknown |
|
| NF- | Subunit of NF- | Inactivated | Cleavage generates a dominant-negative proapoptotic fragment | VFTD (465) | |
| NRF2 | Basic leucin-zipper transcription factor of the NF-E2 family; binds to antioxidant response elements | Inactivated | Overexpression of C-terminal fragment induces apoptosis; gene induction of detoxifying enzymes is abolished | TEVD (208), EELD (366) |
|
| PML-RAR | Fused oncogenic transcription factor in acute promyelocytic leukemia | Inactivated | Cleavage results in retargeting of PML to nuclear bodies | PHLD (523) | |
| RAR | Retinoid acid receptor- | Inactivated | Loss of transcriptional activity | Unknown |
|
| Relish | Drosophila NF- | Inactivated | Loss of transcriptional activity | Unknown |
|
| Sp1 | Constitutive transcription factor | Inactivated | DNA-binding activity abolished | NSPD (590) |
|
| SREBP-1/-2 | Sterol-regulatory element-binding protein-1/-2 involved in cholesterol metabolism | Activated | Nonphysiological cleavage by caspases | SREBP-2: DEPD (468) |
|
| SRF | Serum response factor | Inactivated | DNA binding abolished; loss of, for example, c-fos expression | Unknown |
|
| STAT1 | Signal transducer and activator of transcription-1 | Inactivated | Blockade of interferon and other cytokine signaling | MELD (694) |
|
|
| |||||
| BTF3 | Transcription initiation factor of RNA polymerase II | Unknown | Identified by 2D gel electrophoresis and | Putative site: QSVD (175) |
|
| hnRNPs (A0, A2/B1, A3, C1, C2, I, K, R) | Hetergeneous nuclear ribonucleoproteins involved in pre-mRNA-splicing and transport | Inactivated | Reduced RNA processing | ||
| KHSRP | KH-type splicing regulatory protein (syn. FUSE-binding protein 2), part of a complex that binds to an intronic splicing enhancer | Unknown | Identified by 2D gel electrophoresis and | Putative sites: IRKD (72), AFAD (76), IGGD (91), STPD (102), QLED (114), EDGD (116), SQGD (128) |
|
| NONO/ p54nrb | Non-Pou domain-containing octamer-binding protein (syn. nuclear RNA-binding protein 54-kD, p54nrb), splicing factor | Unknown | Identified by 2D gel electrophoresis and | Putative site: MMPD (421) |
|
| NS1-associated protein1 | RNA-binding protein that interacts with the nonstructural NS1 parvovirus protein | Unknown | Identified by 2D gel electrophoresis | Unknown |
|
| Nucleolin | Abundant protein, involved in rRNAs transcription, ribosome maturation and assembly | Unknown | Putative sites: TEID (455), and AMED (629) or GEID (633) | ||
| RHA | RNA helicase A, mediates interactions between RNA polymerase II and transcription factors | Inactivated | Cleavage results presumably in reduced transcription of particular genes | EEVD (167) | |
| SFRS1 | Member of the SR (serine- and arginine-rich) family of non-snRNP splicing factors, (syn. alternative splicing factor-2 or SRp30a) | Unknown | Identified by 2D gel electrophoresis and | Putative sites: DLKD (139), CYAD (151), VYRD (155), RKLD (176) |
|
| SFRS9 | Member of the SR (serine- and arginine-rich) family of non-snRNP splicing factors, involved in alternative splicing (syn. SRp30c) | Unknown | Identified by 2D gel electrophoresis | Putative site: GWAD (6) |
|
| SRPK1 | Serine/arginine splicing factor protein kinase 1 | Inactivated? | Unknown | See Utz and Anderson[ | |
| SRPK2 | Serine/arginine splicing factor protein kinase 2 | Inactivated? | Unknown | See Utz and Anderson[ | |
| SS-B/La-autoantigen | Involved in RNA biogenesis; Sjogren's syndrome autoantigen | Inactivated | Cleavage presumbably results in disturbed Pol III transcription | DEHD (371) or DEHD (374) |
|
| U1-70-kDa snRNP | Component of the U1 small nuclear ribonucleoprotein complex, involved in pre-mRNA-splicing | Inactivated | Reduced RNA processing | DGPD (341) | |
|
| |||||
| 60S acidic ribosomal protein P0 | Component of the ribosome | Unknown | Identified by 2D gel electrophoresis, not confirmed by | Putative sites: SDED (310), EESD (308), PRED (5) | |
| DAP5 | Death-associated protein 5 (syn. p97, NAT1); member of the eIF4G-family | Activated | Cleavage product stimulates translation from the IRES sites of c-Myc, Apaf-1, DAP5 and XIAP, supporting translation of apoptosis-related proteins. | DETD (792) | |
| eIF2 | Eukaryotic translation initiation factor 2 | Inactivated? | Generation of C-terminally truncated protein might result in protection of protein synthesis from PKR-mediated phosphorylation of eIF2 | AEVD (301) or DGDD (304) | |
| eIF3 | p35 subunit of translation initiation factor eIF3 | Inactivated? | DLAD (242), DYED (256) |
| |
| eIF4B | Eukaryotic translation initiation factor 4B | Inactivated | Generation of N-terminal truncated cleavage product, loss of poly(A)-binding and translation | DETD (45) | |
| eIF4E-BP1 | Eukaryotic translation initiation factor 4E-binding protein 1 | Inactivated | Fragment functions as a dominant-negative inhibitor of CAP-dependent translation | VLGD (25) | |
| eIF4GI | Eukaryotic translation initiation factor 4GI, binds to the 5′ cap structure of mRNAs and facilitates binding of capped mRNA to 40S ribosomal subunits | Inactivated | Inhibition of translation | DLLD (492), DRLD (1136) | |
| eIF4GII | Eukaryotic translation initiation factor 4G II, binds to the 5′ cap structure of mRNAs and facilitates their binding to 40S ribosomal subunits. | Inactivated | Shut-off of cap-dependent translation | Unknown | |
| NAC | Nascent polypeptide-associated complex alpha; subunit of a complex that binds newly synthesized polypeptides and prevents them from incorrect translocation to the ER | Unknown | Identified by 2D gel electrophoresis | Unknown |
|
| PABP4 | Poly(A)-binding protein 4 required for poly(A) shortening and translation initiation | Unknown | Identified by 2D gel electrophoresis | Unknown |
|
| SRP72 | 72-kDa signal recognition particle protein | No effect? | Cleaved SRP72 still transports signal peptide-containing proteins to the ER | SELD (614) |
|
|
| |||||
| pro-IL-1 | Interleukin-1ß precursor | Activated | Essential proinflammatory mediator | YVHD (116) | |
| pro-IL-16 | Interleukin-16 precursor | Activated | Induces T-cell chemotaxis | SSTD (510) |
|
| pro-IL-18 | IFN- | Activated | Induces IFN- | LESD (36) | |
| pro-EMAP-II | Endothelial monocyte-activating polypeptide-II | Activated | Pro-EMAP-II is identical to the p43 component of the aminoacyl-tRNA synthetase complex | Mouse: ASTD (144) | |
| Human: site not conserved | |||||
|
| |||||
| DCC | Deleted in colorectal cancer, tumor suppressor gene | Inactivated | Cleavage product is proapoptotic | LSVD (794) |
|
| EGF-R | Epidermal growth factor receptor | Inactivated | Cleavage inactivates EGF-R and triggering of survial signals | Putative sites: DEED (1006), DMDD (1009) |
|
| ErbB-2 | Receptor tyrosine kinase, functions as a coreceptor with ligand-occupied members of the EGF receptor, ErbB-3 or -4 | Inactivated? | Cleavage of the cytoplasmic part presumably deletes signaling capacity | SETD (45) |
|
| Glutamate receptor | Receptor family involved in neurotransmission | Inactivated | Cleavage of the glutamate receptor subunits GluR1, 2, 3, 4, but not of NMDA receptor subunits results in modified responsitivity to glutamate | Asp 865 | |
| RET | Tyrosine kinase receptor, proto-oncogene involved in Hirschsprung disease and multiple endocrine neoplasia type 2 | RET induces apoptosis via its own cleavage by caspases through the libearation of a proapoptotic domain of RET | VSVD (707), DYLD (1017) |
| |
| TCR ζ | T-cell receptor zeta chain | Inactivated | Cleavage of the cytoplasmic part results in loss of | DTYD (153), and GLLD (28) or YLLD (36) |
|
| TNF-R1 | Tumor necrosis factor receptor-1 (p60) | Inactivated | Cleavage of the cytoplasmic tail at a nonconsensus motif by caspase 7 | GELE (260) |
|
|
| |||||
| GrpL/Gads | Adapter of the Grb2 family in hematopoietic cells, couples to the T-cell receptor and SLP-76 to regulate transcription factors such as NF-AT | Inactivated | Deletion of the C-terminal SH3 domain prevents recruitment of SLP-76 and leads to desensitization of antigen receptor signaling | DIND (235) | |
| TRAF1 | TNF-R-associated factor 1 | Inactivated | C-terminal cleavage product blocks NF- | LEVD (163) | |
| TRAF3 | TNF-R-associated factor 3 | Inactivated? | Altered cellular distribution of the cleavage product | EEAD (348), ESVD (368) |
|
| TXBP151 | HLTLV-1 Tax-binding protein, antiapoptotic A20-binding protein | Inactivated | Loss of antiapoptotic effect of TXBP15 | Unknown |
|
|
| |||||
| ETK/BMX | Member of the Btk/Tec family of kinases | Activated | Overexpression of the fragment induces apoptosis | ETK: DFPD (242) and a second unknown site |
|
| Fyn | T-cell Src kinase | Activated | Removal of N-terminal myristoylation sites leads to relocalization and increased activity | EERD (19) | |
| Lyn | B-cell Src kinase | Activated | Removal of N-terminal myristoylation sites leads to relocalization and increased activity | DGVD (18) |
|
| Src | pp60(c-Src), proto-oncogene | Inactivated? | Antiapoptotic effect is abolished | Unknown |
|
|
| |||||
| AKT | Important survival kinase (syn. PKB) | Inactivated | Loss of kinase activity and antiapoptotic function | TVAD (108), EEMD (119), ECVD (462) | |
| CaMK II | Calcium/calmodulin-dependent kinase II | Inactivated? | Effect on kinase activity not tested | Unknown |
|
| CaMK IV | Calcium/calmodulin-dependent kinase IV | Inactivated | Cleavage within catalytic domain results in loss of activity | PAPD (176), YWID (31) |
|
| CaMKK | CaMK kinase | Inactivated? | Effect on kinase activity not tested | Unknown |
|
| CaMKLK | Ca2+/calmodulin-dependent protein kinase (CaMK)-like kinase | Dysregulated | C-terminal fragment retains kinase activity, while N-terminal fragment promotes apoptosis | Rat: DEND (62) (Human, mouse: putative DEND site at 369) |
|
| HPK-1 | Hematopoietic progenitor kinase-1, Ste20-related protein kinase | Dysregulated | Proapoptotic cleavage converts an activator into an inhibitor of NF- | DDVD (385) | |
| MASK | Mst3 and SOK1-related kinase (MASK) of the germinal center kinase family | Activated | Proapoptotic, if overexpressed | DESD (305) |
|
| MEK | MAP kinase kinase | Inactivated | Direct cleavage by caspases uncertain. Proteolysis results in reduced Erk1/2 phosphorylation | Unknown |
|
| MEKK1 | MEK kinase-1; involved in stress signaling | Activated | Cleavage product is constitutively active, intracellularly redistributed and proapoptotic | Mouse: DTVD (874) (Human and rat: not conserved) | |
| Mst1 | Mammalian STE20-related kinase-1 (Krs2); involved in stress signaling | Activated | Removal of C-terminal regulatory domain results in constitutive activity, relocalization and activation of stress kinases and caspases. | DEMD (326) | |
| Mst2 | Mammalian STE20-related kinase (Krs1), involved in stress signaling | Activated | Cleavage results in a constitutively active kinase | DELD (322) |
|
| Mst3 | Mammalian STE20-related kinase, involved in stress signaling | Activated | Cleavage results in a constitutively active kinase. Overexpression of the C-terminal kinase fragment induces apoptosis. | AETD (313) |
|
| PAK2 | P21-activated kinase 2 (syn. PAK65; PAK | Activated | Constitutive activation by separation of N-terminal regulatory and C-terminal catalytic domain, induces apoptotic morphology | SHVD (212) | |
| PKC | Protein kinase C delta | Activated | Constitutively active kinase, proapoptotic | DMQD (329) | |
| PKC | Protein kinase C epsilon | Activated | Constitutively active kinase | Human: SSPD (383), Mouse: SATD (383) | |
| PKC | Protein kinase C eta | Activated | Kinase-active fragment is proapoptotic | Unknown site in or upstream of the V3 region |
|
| PKC | Protein kinase C mu | Activated | Increased sensitivity to genotoxic stress | CQND (378) | |
| PKC | Protein kinase C theta | Activated | C-terminal fragment is constitutively active and proapoptotic | DEVD (354) | |
| PKC | Protein kinase C zeta | Activated | Constitutively active kinase | EETD (210), DGVD (239) | |
| PKR | Double-stranded RNA-dependent protein kinase, involved in antiviral response | Activated | Caspase-dependent activation leads to eIF2- | DLPD (251) |
|
| PRK1 | PKC-related kinase-1 (syn. PKN) | Activated | Constitutively active kinase | Unknown |
|
| PRK2 | PKC-related kinase-2 | Activated? | Proapoptotic; C-terminal fragment inhibits AKT and PDK-1 | DITD (117) | |
| Raf-1 | ‘Ras-associated factor 1’, important kinase in mitogenic signaling | Inactivated | Cleavage results in loss of Raf-1 antiapoptotic function | Unknown |
|
| RIP-1 | Receptor-interacting kinase-1, component of the TNF-R1 DISC | Inactivated | Proapoptotic cleavage by caspase-8 results in inhibition of NF- | LQLD (324) | |
| ROCK-1 | Rho-associated kinase-1 | Activated | Caspase-mediated activation results in activation of myosin light chain kinase and membrane blebbing | DETD (1113) | |
| SLK | STE20-related kinase, JNK-pathway | Activated | Two cleavage products with distinct activities: N-terminal kinase promotes apoptosis and cytoskeletal rearrangement, the C-terminal fragment disassembles actin fibers | Mouse: DTQD (436 (site not conserved in human) |
|
| SPAK | STE20/SPS1-related, proline alanine-rich kinase of STE20 kinase family | Unknown | Rat: DEMD (398) Human: DEMD (392) Mouse: DEMD (402) |
| |
| p70S6K | p70 form of S6 kinase | Inactivated | Direct cleavage by caspases uncertain | Unknown |
|
|
| |||||
| Calcineurin | Calmodulin-dependent phosphatase involved in NFAT activation and cytokine synthesis | Activated | Caspase-mediated constitutive activation triggers NF-AT activation and IL-2 release | DFGD (386) | |
| PP2A | Protein phosphatase 2A | Activated | Caspases cleave regulatory | DEQD (218) |
|
|
| |||||
| FTase | Farnesyltransferase, attaches farnesyl groups to cysteine residues of proteins | Inactivated | Cleavage of | VSLD (59) |
|
| GGTase I | Geranylgeranyltransferase I, attaches geranylgeranyl groups to cysteine residues | Inactivated | Cleavage of | VSLD (59) |
|
| O-GlcNAase | No effect | Cleavage has no effect on enzyme activity | Unknown |
| |
| tTG | Tissue transglutaminase (TG-2) crosslinks proteins and assembles scaffolds that prevent leakage of intracellular components | Inactivated | Cleaved late in apoptosis, results in loss of crosslinking activity. | Unknown |
|
|
| |||||
| Calpastatin | Calpain inhibitor | Inactivated | Decreased inhibition of calpain | ALDD (137), LSSD (203), ALAD (404) | |
| Cbl | Adaptor protein with ubiquitin ligase activity, negative regulator of T-cell activation, downregulates receptor tyrosine kinases by ubiquitinylation | Unknown | Unknown |
| |
| Cbl-b | Cbl-related protein with ubiquitin ligase activity, downregulates receptor tyrosine kinase and PI3K signaling | Unknown | Unknown |
| |
| Nedd4 | ‘Neural-expressed developmentally downregulated gene4 protein’, ubiquitin protein ligase | Unknown | Cleavage products do not affect apoptosis, enzyme activity of NEDD4 presumably not impaired | DQPD (206) |
|
| PA28 | Proteasome activator 28 | Unknown | DGLD (80) |
| |
| PAI-2 | Plasminogen activator inhibitor type 2 | Inactivated | Function as putative cytoprotective protease inhibitor may be abolished | Unknown |
|
| UFD2 | Ubiquitin fusion degradation protein-2, with E3 ligase activity | Inactivated | E3 activity is abolished | VDVD (123), MDID (109) |
|
|
| |||||
| Cdc42 | Ras-related GTP-binding protein, provides survival signals and controls cytoskeletal architecture | Inactivated | Antiapoptotic function abolished. Mutation of the cleavage site of Cdc42 provides protection | DLRD (121) |
|
| D4-GDI | D4-GDP dissociation inhibitor (syn. Rho-GDI 2; Ly-GDI), inhibitor of Rho GTPases | Inactivated | Cleavage product translocates to the nucleus, defective Rho GTPase signaling | DELD (19) | |
| Rabaptin-5 | Small GTPase, rate-limiting component in membrane fusion in the early endocytotic pathway | Inactivated | Cleavage blocks endosome fusion | DESD (438) |
|
| Rac | Ras-related GTP-binding protein | Inactivated? | DLRD (121) |
| |
| Ran-GAP1 | Ran GTPase activating protein 1, involved in nuclear transport | Unknown | May be involved in alterations of nuclear pore transport. Cleavage not confirmed | Unknown |
|
| Ras-GAP | Ras GTPase-activating protein | Activated, inactivated | Limited caspase cleavage: N-terminal fragment is antiapoptotic by activating the PI3K pathway. Increased caspase levels: further cleavage into two proapoptotic fragments | DEGD (157), DTVD (459) | |
| TIAM1 | Rac-specific guanine nucleotide exchange factor | Inactivated | Functional inactivation, cannot stimulate GDP loading of Rac | DETD (993) |
|
| Vav-1 | Hematopoietic proto-oncogene, guanine nucleotide exchange factor | Inactivated | Fails to induce IL-2 transcription; diminished capacity to activate AP-1, NF- | DQID (150), DLYD (161) |
|
|
| |||||
| CCT- | CTP : phosphocholine cytidylyltransferase | Activated | Cleavage results in nuclear export | TEED (28) |
|
| IP(3)R-1/-2 | Inositol 1,4,5-triphosphate receptor-1 and -2 | Inactivated | Decrease in IP(3)-gated Ca2+ channel activity | Mouse IP(3)R-1: DEVD (1892) | |
| PIP5K-I | Phosphatidylinositol phosphate 5-kinase-I | Inactivated | Inactivation contributes to progression of apoptosis | DIPD (279) |
|
| PDE4A5 | cAMP-specific phosphodiesterase 4A5 | Dysregulated | Cleavage removes SH3-binding domain and results in altered intracellular targeting and Lyn kinase interaction | Mouse: DAVD (72) |
|
| PDE5A1 | cGMP-binding phosphodiesterase 5A1 | Inactivated? | Unknown |
| |
| PDE6 | cGMP-binding phosphodiesterase 6 | Inactivated? | Reduced cGMP-hydrolyzing activity | Putative site: DFVD (167) |
|
| PDE10A2 | cGMP-binding phosphodiesterase 10A2 | Inactivated? | Putative site: Rat: DLFD (315), Human: DLFD (333) |
| |
| PMCA-2 | Neuron-specific plasma membrane Ca2+ATPase isoform 2 | Unknown | Putative site: EEID (1072) |
| |
| PMCA-4 | Ubiquitous plasma membrane Ca2+ATPase isoform 4 | Inactivated/activated? | Cleavage-mediated inactivation may result in calcium overload and secondary necrosis. | DEID (1080) | |
| iPLA(2) | Calcium-independent phospholipase A2 | Activated | Fragment accelerates phospholipid turnover and contributes to apoptotic membrane changes | DVTD (183) |
|
| cPLA(2) | Cytosolic phospholipase A2
| Inactivated | Cleavage blocks PLA2 activity and prevents production of lipid mediators; may have immunosuppressive function | DELD (336) | |
| PLC- | Phospholipase C- | Inactivated | Phosphorylated PLC is resistant against cleavage. Cleavage facilitates apoptosis | AEPD (770) |
|
|
| |||||
| Androgen receptor | Polyglutamine tract protein, defective in spinal bulbar muscular atrophy (Kennedy's disease) | Aggregates | Aggregation of the truncated protein may result in neurodegeneration | DEDD (155) | |
| APLP1 | Amyloid precursor protein-like protein -1, related to APP | Aggregates? | Cleavage generates a cytotoxic C-terminal fragment similar to C31 in APP | VEVD (620) |
|
| APP | Cleavage results in generation of the proapoptotic C-terminal C31-peptide. | VEVD (739) | |||
| Ataxin-3 | Polyglutamine tract protein defective in spinocerebrellar ataxia type 3 | Aggregates | Aggregation of the truncated protein may result in neurodegeneration | Putative sites: LISD (145), DLPD (171), LDED (225), DEED (228) | |
| Atrophin-1 | Polyglutamine tract protein defective in Dentatorubral pallidalysian atrophy (syn. DRPLA protein) | Aggregates | Aggregation of the truncated protein may result in neurodegeneration | DSLD (109) | |
| Calsenilin | Member of the recoverin family of calcium-binding proteins, interacts with presenilins | Inactivated | May be involved in Alzheimer's disease | DSSD (64) |
|
| Huntingtin | Polyglutamine tract protein defective in Huntington's disease | Aggregates | N-terminal fragment is cytotoxic and triggers caspase activation | DSVD (513), DEED (530), IVLD (586) | |
| Parkin | Involved in Parkinson's disease | Inactivated | Protein degradation abolishes antiapoptotic function | LHTD (126) |
|
| Presenilin-1 | Involved in Alzheimer's disease | Inactivated | Cleavage abolishes interaction with ß-catenin and antiapoptotic function | AQRD (345) | |
| Presenilin-2 | Involved in Alzheimer's disease | Inactivated | Cleavage abolishes interaction with ß-catenin and disables antiapoptotic function | DSYD (329) | |
|
| |||||
| Bcl-2 homologs | Viral Bcl-2-homolog encoded by | No effect | Unlike mammalian Bcl-2, most viral Bcl-2 proteins are not cleaved. | DCVD (31) |
|
| CrmA | Cytokine response modifier A, serpin-like caspase inhibitor of poxvirus | Activated | Unlike IAPs, CrmA requires peptide bond hydrolysis for caspase-inhibitory action | LVAD (303) |
|
| M2 (influenza A) | Virus-specific ion channel membrane protein of influenza A virus | Unknown | Cleavage may attenuate virus production | DVDD (88) |
|
| NP (influenza A and B) | nucleocapsid protein of influenza A and B viruses | Unknown | Cleavage may attenuate virus production | Influenza A: METD (16), Influenza B: MDID (7), SEAD (61) | |
| NS5A (HCV) | Nonstructural protein 5A of hepatitis C virus | Unknown | N-terminal deleted protein translocates to the nucleus and has transactivating function | Putative sites: TEVD (154), SGVD (396) | |
| Nucleoporin (TGEV) | Transmissible gastroenteritis coronavirus (TGEV) nucleocapsid protein | Unknown | Cleavage may limit virus production | VVPD (359) |
|
| p35 | pancaspase inhibitor of baculovirus | Activated | Cleavage is required for caspase inhibition by p35 | DQMD (87) | |
|
| |||||
| AHNAK | Autoantigen in systemic lupus Erythematosus. DNA-binding phosphoprotein | Unknown | Unknown |
| |
| CPSII | Carbamoyl phosphate synthetase II, required for pyrimidine nucleotide synthesis | Inactivated | EAVD (1371) in catalytic B2 domain and VACD (1143) in allosteric B3 domain |
| |
| F1A | Mammalian homolog of FEM-1 (syn. FEM1 | Acitvated? | F1A | DNID (342) |
|
| FEM-1 | Involved in sex-specific cell elimination in | Activated? | Caspase cleavage promotes apoptosis-inducing property of FEM-1, which interacts with Ced-4 | ELLD (320) |
|
| FKBP46 | FK506 binding protein 46, insect nuclear immunophilin | Unknown | Unknown |
| |
| GCL | Glutamate- | Inactivated | Cleavage of the catalytic subunit results in loss of the antioxidant glutathione | AVVD (499) |
|
| Hsp90 | Unknown | DEED (259) |
| ||
| PDC-E2 | Pyruvate dehydrogenase complex E2, autoantigen. | Unknown | Cleavage confirmed by | Unknown |
|
| SET | Product of the putative set oncogene | Unknown | SNHD (18) |
| |
aIf not otherwise indicated, the cleavage sites refer to the human sequence.
bDuring typesetting of this manuscript additional caspase substrates have been identified including the large subunit of RNA polymerase II,[336] the vesicle-tethering Golgi protein p. 115,[337] the neuronal Ras-guanine nucleotide exchange factor GRASP-1,[338] the hematopoietic transcription factor FL1-1[339] SRPK1 and SRPK2, two kinases of the serine/argine splicing factors,[340] the K10 retroviral polyprotein HERV-K10gag,[341] adenovirus early region 1A proteins,[342] and baculovirus apoptotic suppressor protein p 49.[343]